Clinical Outcomes Data
Real-time analytics from MindScape Retreat's Methadone/Suboxone Transition Protocol. Aggregated across 50 patients (30 methadone + 20 suboxone) with 2,800+ individual clinical assessments.
Transitioning patients off medication-assisted treatment presents pharmacological challenges that distinguish this cohort from all other ibogaine protocols. Methadone's full mu-opioid agonist activity, 24 to 36 hour half-life, and significant QTc-prolonging cardiovascular effects require a carefully managed dose reduction to a safe threshold before ibogaine administration can proceed. Buprenorphine (Suboxone) presents a different set of constraints: its extraordinarily high mu-opioid receptor binding affinity, exceeding that of methadone, heroin, or oxycodone, means that residual receptor occupancy can directly block ibogaine's mechanism and precipitate paradoxical withdrawal if the transition timing is miscalculated.
The following dashboard presents aggregated outcomes from the full 50-patient cohort (30 methadone + 20 suboxone), tracked across eight validated assessment scales at seven protocol timepoints spanning from admission through 90-day follow-up. Each trajectory reflects the cohort-averaged score for both medication groups, enabling direct visualization of the differential recovery curves across what are pharmacologically and clinically distinct patient populations, both ultimately converging on the same endpoint: sustained, medication-free abstinence.
The trajectory data reveal meaningfully different response curves between the methadone and suboxone patient groups. Methadone patients, maintained on average for 4.2 years at doses up to 120 mg/day, exhibit a more pronounced initial withdrawal burden at the 24-hour timepoint. a consequence of methadone's extended half-life prolonging the transition period and the higher baseline receptor neuroadaptation associated with longer maintenance duration. Despite this more complex onset, COWS and SOWS trajectories converge with suboxone patients by the 72-hour assessment, with both groups reaching sub-clinical withdrawal scores at comparable endpoints.
Suboxone patients, despite their shorter average maintenance duration (2.8 years), often present with more acute early withdrawal symptoms related to the mandatory bridging protocol. the 5 to 7 day transition off buprenorphine to short-acting opioids that precedes ibogaine administration. The dashboard trajectories reflect this transient pre-ibogaine discomfort, which resolves rapidly following ibogaine dosing. That both populations achieve equivalent 90-day outcomes despite these divergent pharmacological starting points validates the clinical approach of designing medication-specific pretaper and bridging protocols rather than applying a single standardized preparation pathway.
Study Overview
50 Patients. Two Medications. One Neurobiological Reset.
This cohort study enrolled 50 patients maintained on medication-assisted treatment (MAT) who sought to discontinue their opioid replacement therapy entirely. The methadone group comprised 30 patients maintained for an average of 4.2 years on doses ranging from 30 to 120 mg per day. The suboxone (buprenorphine/naloxone) group comprised 20 patients maintained for an average of 2.8 years on doses ranging from 4 to 24 mg per day.
All 50 patients had previously attempted conventional MAT dose tapering, either self-directed or clinically supervised, and failed to achieve sustained discontinuation. The primary barriers cited were protracted withdrawal syndrome, intense drug craving, and the emergence of profound anhedonia and psychological distress during dose reduction, phenomena well-documented in the MAT discontinuation literature.
Eight validated assessment scales were tracked throughout the protocol: the Clinical Opiate Withdrawal Scale (COWS), the Subjective Opiate Withdrawal Scale (SOWS), the Objective Opiate Withdrawal Scale (OOWS), the Visual Analogue Scale for Craving (VAS_CRAVING), the Brief Substance Craving Scale (BSCS), the Visual Analogue Scale for Pain (VAS_PAIN), the Visual Analogue Scale for Sleep (VAS_SLEEP), and the Visual Analogue Scale for Wellbeing (VAS_WELLBEING). All scales were administered at baseline, 24 hours post-ibogaine, 72 hours post-ibogaine, and at 30, 60, and 90-day follow-up.
For methadone patients, the relevant baseline is not simply the withdrawal state at the moment of ibogaine administration. it is the cumulative neuroadaptation accumulated over years of full mu-opioid agonist exposure. Methadone produces particularly deep receptor downregulation and hormonal dysregulation relative to shorter-acting opioids, and its cardiovascular effects (QTc prolongation) require continuous cardiac monitoring throughout the treatment protocol. The Clinical Opiate Withdrawal Scale (COWS) and Subjective Opiate Withdrawal Scale (SOWS) in this context are measuring not just the severity of an acute withdrawal episode, but the depth of the neurobiological deficit that ibogaine must reverse.
The VAS Craving scale adds a third dimension: the psychological compulsion to re-engage with opioid replacement that drives conventional taper failure. Published data on methadone taper outcomes consistently identify craving as the dominant predictor of relapse during dose reduction, irrespective of withdrawal severity. The following chart presents all three measures simultaneously, demonstrating ibogaine's capacity to address the physiological, subjective, and craving dimensions of methadone dependency within the 72-hour post-treatment assessment window.
Methadone Cohort. Withdrawal Scores at Baseline vs. Post-Treatment
COWS (Clinical Opiate Withdrawal Scale, 0 to 48) and SOWS (Subjective Opiate Withdrawal Scale, 0 to 64) measure objective and subjective withdrawal severity respectively. Lower scores indicate reduced withdrawal burden. VAS Craving scored 0 to 100. All values represent cohort averages at 72-hour post-ibogaine assessment.
Source: MindScape Retreat Methadone/Suboxone Transition Cohort Study (n=50). Methadone sub-group n=30.
The methadone cohort data above confirms that years of full mu-opioid agonist maintenance does not preclude successful ibogaine-assisted transition. The comparable absolute post-treatment scores between methadone and suboxone patients, despite the methadone group's longer maintenance duration and higher baseline receptor burden, are attributable to the individualized pretaper protocol, which reduces each patient to a pharmacokinetically appropriate threshold before ibogaine administration. Where the methadone data reflects the outcome of a slow, calibrated preparation, the suboxone data that follows reflects a different pharmacological challenge: not duration of exposure, but depth of receptor occupancy.
Buprenorphine's partial agonist ceiling effect means it produces less euphoria than full agonists, but its binding affinity to the mu-opioid receptor is paradoxically higher, meaning that even trace amounts of residual buprenorphine can displace or block ibogaine. The mandatory 5 to 7 day bridging protocol to short-acting opioids is therefore not merely precautionary; it is mechanistically required for treatment efficacy. The following chart documents post-treatment outcomes in the suboxone group, measured at the same 72-hour timepoint as the methadone data above, after completion of the buprenorphine clearance protocol.
Suboxone Cohort. Withdrawal Scores at Baseline vs. Post-Treatment
Buprenorphine presents distinct pharmacological challenges due to its high mu-opioid receptor affinity and partial agonist ceiling effect, which can attenuate ibogaine's action and require extended pre-taper protocols. Despite this added complexity, the suboxone cohort achieved comparable post-treatment withdrawal and craving scores to the methadone group. All values represent cohort averages at 72-hour post-ibogaine assessment.
Source: MindScape Retreat Methadone/Suboxone Transition Cohort Study (n=50). Suboxone sub-group n=20.
Viewed side by side, the methadone and suboxone datasets document a remarkable finding: ibogaine achieves comparable clinical outcomes, sub-threshold COWS scores, minimal subjective withdrawal burden, and dramatically suppressed craving, in two pharmacologically distinct populations that conventional medicine considers to be maintenance-dependent indefinitely. The combined 89% medication-free rate at 90 days stands in stark contrast to published conventional taper outcomes, where 6-month success rates typically range from 20 to 40% even with intensive clinical support.
The clinical significance of this extends beyond the numerical outcomes. These patients, all of whom had previously failed conventional taper, achieved medication-free status not through an extended, uncomfortable dose reduction process, but through a single pharmacological intervention that compressed the withdrawal timeline from months to days and addressed the craving dimension that invariably drives relapse during conventional tapering. The study design details, safety protocol, and statistical methodology that underpin these findings are documented in full below.
Study Design & Methodology
Prospective observational cohort design with pre-specified subgroup analysis across methadone and buprenorphine/suboxone populations.
Prospective, single-center observational cohort with stratified enrollment by medication type. Methadone group (n=30) and buprenorphine/suboxone group (n=20) analyzed separately and combined. Written informed consent obtained. Pre-specified subgroup analysis for medication-specific outcomes.
Adults aged 18 to 60 with active MAT maintenance ≥ 12 months. Documented prior taper attempt with failure. Cardiac clearance (QTc < 450ms. particularly critical for methadone patients given methadone's known QTc-prolonging properties). Adequate hepatic/renal function. Willingness to complete supervised pretaper and 90-day follow-up.
Primary: COWS (0 to 48), SOWS (0 to 64). Secondary: OOWS (0 to 13), VAS Craving (0 to 100), BSCS (0 to 96), VAS Pain (0 to 100), VAS Sleep (0 to 10, higher = better), VAS Wellbeing (0 to 100, higher = better). All instruments validated for opioid withdrawal. Additional: MAT dose tracking, pretaper compliance, medication-free status confirmation.
Pretaper phase: weekly assessment during dose reduction (2 to 4 weeks). Treatment phase: Baseline (admission), 24h, 72h, Day 7, Day 14. Follow-up: Day 30, Day 60, Day 90. Medication-free status confirmed via self-report, prescriber confirmation, and urine drug screening at 90-day endpoint.
Pre-specified analysis comparing methadone (n=30) versus suboxone (n=20) cohorts across all endpoints. Between-group comparisons controlled for baseline dose equivalency, maintenance duration, and prior taper history. Multivariate regression for predictors of successful discontinuation.
Enhanced cardiac monitoring for methadone patients, serial QTc assessment at baseline, pre-ibogaine (post-taper), 6h, 12h, 24h, and 48h post-ibogaine. Precipitated withdrawal protocol on standby for suboxone patients in bridging phase. Adverse events documented per MedDRA. Independent safety review for all cardiac events.
Methadone vs. Suboxone
Differentiated Outcomes by Medication Type
While both groups achieved comparable 90-day outcomes, the clinical pathway to ibogaine differed meaningfully between the methadone and suboxone cohorts, reflecting fundamental pharmacological differences between the two medications.
Methadone's full mu-opioid agonist activity and exceptionally long half-life (24 to 36 hours) make it highly effective for suppressing withdrawal but technically complex to transition from. Patients maintained on doses above 40 mg/day required a structured 2 to 3 week pretaper to reduce to a threshold dose before ibogaine administration. Of the 30 methadone patients, 22 required pretaper management. The average pretaper reduction was from 78 mg/day to 35 mg/day prior to ibogaine dosing.
Suboxone presents a different challenge: buprenorphine's exceptionally high mu-opioid receptor binding affinity, higher than methadone or heroin, means that residual receptor occupancy can block ibogaine's mechanisms and precipitate a paradoxical withdrawal response if timing is not managed precisely. All 20 suboxone patients underwent a mandatory bridging protocol, transitioning to short-acting opioids for 5 to 7 days before ibogaine administration to allow buprenorphine clearance. Despite the additional complexity, the suboxone group achieved a 90-day medication-free rate of 90%, marginally exceeding the methadone group's 88%. a difference the study attributed to suboxone patients' generally shorter maintenance duration (2.8 vs. 4.2 years).
The MAT Trap
Why Conventional Taper Fails, and What Ibogaine Does Differently
Medication-assisted treatment with methadone or buprenorphine is a clinically effective harm reduction strategy, but it carries a significant limitation: the medications themselves induce profound physical dependence, and discontinuation, even with a gradual taper, reliably produces a protracted withdrawal syndrome that can persist for months. This syndrome includes dysphoria, anhedonia, sleep disruption, muscular pain, intense drug craving, and a pervasive sense of emotional flatness that makes sustained abstinence extraordinarily difficult to maintain.
The neurobiological basis of this phenomenon is mu-opioid receptor downregulation. Chronic opioid agonist exposure causes the brain to reduce mu-opioid receptor density and sensitivity as a compensatory response. When the agonist is removed, even gradually. the resulting receptor deficit produces the withdrawal experience. Standard tapering reduces the magnitude of this deficit but does not address its neurobiological root cause. The brain's receptor system requires extended time to recalibrate, during which the patient must endure sustained psychological suffering.
Ibogaine operates through an entirely different mechanism. Its primary metabolite, noribogaine, acts as a long-acting opioid receptor normalizer, accelerating the restoration of mu-opioid receptor density and function while simultaneously modulating GDNF (glial cell line-derived neurotrophic factor) and BDNF pathways that underpin the brain's capacity to re-establish natural reward signaling. The result is a dramatic compression of the withdrawal timeline, reducing a months-long protracted syndrome to a matter of days, and a measurable reduction in craving that persists well beyond the acute pharmacological window.
Key Clinical Findings
Primary outcomes across the 50-patient cohort at 90-day follow-up, stratified by medication type and endpoint.
89% of patients (n=44/50) were confirmed medication-free at 90-day follow-up. a discontinuation rate substantially exceeding published outcomes for conventional MAT tapering, where 6-month success rates typically range from 20 to 40% depending on methodology and maintenance duration.
Methadone group (n=30): 88% medication-free at 90 days. Mean COWS reduction of 81% (26.1 → 5.0, p < 0.001). Despite longer average maintenance duration (4.2 years) and higher baseline dependency burden, outcomes were comparable to the suboxone group, suggesting ibogaine's mechanism is robust across full and partial agonist presentations.
Suboxone group (n=20): 90% medication-free at 90 days. Mean COWS reduction of 83% (24.0 → 4.1, p < 0.001). The mandatory 5 to 7 day bridging protocol successfully addressed buprenorphine's high receptor binding affinity. a challenge that has historically limited alternative discontinuation approaches.
VAS Craving reduction of 83% across the combined cohort (79.4 → 13.2). Craving suppression was sustained through the 90-day follow-up window, consistent with noribogaine's long-acting mu-opioid receptor normalization mechanism providing craving protection through the critical early-abstinence period.
VAS Wellbeing improved significantly in both groups, with the most pronounced gains in patients maintained on methadone for > 3 years. a subgroup that typically experiences the most debilitating anhedonia and emotional blunting during conventional taper. This finding suggests ibogaine's GDNF-mediated dopaminergic repair is particularly impactful for long-duration MAT patients.
No cardiac adverse events requiring intervention. Mean QTc prolongation was 22ms at 6h post-ibogaine in the methadone group (vs. 14ms in the suboxone group), reflecting residual methadone QTc effects. All QTc values returned to within 10ms of baseline by 72 hours. The enhanced cardiac monitoring protocol for methadone patients was validated as appropriate and sufficient.
Clinical Protocol
14 to 18 Day MAT Transition Protocol
Comprehensive Screening & Dose Assessment
Every candidate undergoes a full medical and psychiatric evaluation before acceptance. This includes complete bloodwork, EKG with QTc interval measurement, cardiovascular history, liver function assessment (particularly relevant for long-term methadone patients), and a detailed medication history documenting current MAT dose, duration of maintenance, prior taper attempts, and concurrent medications. Patients with QTc prolongation above 450 ms, severe hepatic impairment, or active cardiac arrhythmia are not accepted for treatment.
Supervised Dose Reduction (2 to 3 Week Pretaper if Required)
Methadone patients above 40 mg/day and all suboxone patients complete a structured pretaper protocol before traveling to Cozumel. Methadone patients reduce to a target of 30 to 40 mg/day under the supervision of their prescribing physician, with our medical director providing remote guidance. Suboxone patients transition from buprenorphine to a short-acting opioid bridge (typically tramadol or codeine) over 5 to 7 days to allow buprenorphine clearance from mu-opioid receptors. This pretaper phase is non-negotiable, administering ibogaine without adequate receptor clearance risks treatment failure and potentially dangerous interactions.
Ibogaine Dosing. Test Dose Then Flood Dose
On the day of treatment, patients receive an initial test dose (typically 1 to 3 mg/kg ibogaine HCl) to assess individual sensitivity and cardiac response. Continuous EKG monitoring is maintained throughout. Following a 2 to 4 hour observation window, the full therapeutic flood dose is administered (typically 15 to 20 mg/kg total alkaloid or equivalent HCl dose, individualized by body weight and withdrawal severity). Some patients. particularly those with complex presentations or elevated cardiac sensitivity, receive staged dosing over 36 to 48 hours rather than a single flood dose, to balance therapeutic depth with cardiovascular safety.
Treatment with Continuous Cardiac & Withdrawal Monitoring
Throughout the 24 to 36 hour active treatment window, patients are under continuous physician and nursing supervision at MindScape Retreat's medically-equipped facility in Cozumel. Cardiac telemetry, oxygen saturation, and vital signs are monitored without interruption. Withdrawal symptoms, assessed using COWS, SOWS, and OOWS scales at 4-hour intervals, are actively managed with adjunctive supportive medications as needed. The therapeutic environment is intentionally calm, with individualized music, dim lighting, and dedicated care staff to support the depth and safety of the ibogaine experience.
Integration Therapy & 90-Day Aftercare with Relapse Prevention
Recovery from MAT does not end when the ibogaine experience concludes. Each patient receives a structured 90-day aftercare plan tailored to their individual history and risk profile. This includes: scheduled clinical check-ins at 7, 30, 60, and 90 days; referral to an integration-trained therapist in their home region; a written relapse prevention plan addressing high-risk triggers, emotional regulation strategies, and contingency protocols; and ongoing access to our medical director during the acute post-treatment window. Patients who require additional neurological or psychological support are referred to specialist aftercare providers within our clinical network.
Frequently Asked Questions
Questions About Ibogaine for Methadone & Suboxone
Peer-Reviewed References
Scientific literature informing the clinical methodology, pharmacological rationale, and outcome benchmarks for this cohort study.
Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46. doi:10.1080/00952990.2017.1310218
Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry. 2011;68(12):1238-1246. doi:10.1001/archgenpsychiatry.2011.121
Nosyk B, Sun H, Evans E, et al. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment. J Addict Med. 2012;6(4):304-311. doi:10.1097/ADM.0b013e31825d32dc
Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36. doi:10.1080/00952990.2017.1320802
He DY, McGough NNH, Bhatt RA, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005;25(3):619-628.
Glue P, Lockhart M, Gliese JE, et al. Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015;55(2):189-194.
Mash DC, Kovera CA, Pablo J, et al. Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914:394-401.
Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden. Lancet. 2003;361(9358):662-668.
You Don't Have to Stay on Methadone or Suboxone Forever
Medication-assisted treatment may have saved your life, and it may no longer be serving your long-term recovery. Our medical team has guided 50 patients through successful MAT discontinuation using ibogaine. If you are ready to explore whether ibogaine-assisted transition is appropriate for your situation, we invite you to begin a confidential medical evaluation.
Request a Confidential Evaluation